










































AMYPAD Diagnostic and Patient Management Study
Citation for published version:
Frisoni, GB, Barkhof, F, Altomare, D, Berkhof, J, Boccardi, M, Canzoneri, E, Collij, L, Drzezga, A, Farrar, G,
Garibotto, V, Gismondi, R, Gispert, J-D, Jessen, F, Kivipelto, M, Alves, IL, Molinuevo, J-L, Nordberg, A,
Payoux, P, Ritchie, C, Savicheva, I, Scheltens, P, Schmidt, ME, Schott, J, Stephens, A, van Berckel, B,
Vellas, B, Walker, Z & Raffa, N 2019, 'AMYPAD Diagnostic and Patient Management Study: Rationale and
design' Alzheimer's & Dementia, vol. 15, no. 3. DOI: 10.1016/j.jalz.2018.09.003
Digital Object Identifier (DOI):
10.1016/j.jalz.2018.09.003
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
















































































































109Giovanni B. Frisonia,b,c,*, Frederik Barkhofd,e, Daniele Altomarec,f, Johannes Berkhofg,
Marina Boccardia,c, Elisa Canzoneria, Lyduine Collijd, Alexander Drzezgah, Gill Farrari,
Valentina Garibottoj,k, Rossella Gismondil, Juan-Domingo Gispertm,n, Frank Jesseno,p,
Miia Kivipeltoq,r,s,t, Isadora Lopes Alvesd, Jose-Luis Molinuevom, Agneta Nordbergq,r,
Pierre Payouxu,v, Craig Ritchiew, Irina Savichevax, Philip Scheltensy, Mark E. Schmidtz,
Jonathan Schottaa, Andrew Stephensab, Bart van Berckeld, Bruno Vellasac,ad, Zuzana Walkerae,af,
Nicola Raffaag
aLaboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland
bMemory Clinic, University Hospital of Geneva, Geneva, Switzerland
cLaboratory of Alzheimer’s Neuroimaging and Epidemiology (LANE), Saint John of God Clinical Research Centre, Brescia, Italy
dDepartment of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands
eInstitutes of Neurology and Healthcare Engineering, UCL, London, United Kingdom
fDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
gDepartment of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands
hDepartment of Nuclear Medicine, University Hospital of Cologne, University of Cologne and German Center for Neurodegenerative
Diseases (DZNE), Germany
iLife Sciences, GE Healthcare, Amersham, Buckinghamshire, United Kingdom
jDivision of Nuclear Medicine and Molecular Imaging, Department of Medical Imaging, University Hospitals of Geneva, Geneva, Switzerland
kNIMTlab, Faculty of Medicine, Geneva University, Geneva, Switzerland
lPiramal Imaging, Medical Affairs, Berlin, Germany
mBarcelonabeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain
nCentro de Investigacion Biomedica en Red de Bioingenierıa, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
oDepartment of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany
pGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
qDepartment of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics,
Karolinska Institutet, Stockholm, Sweden
rAging Theme, Karolinska University Hospital Stockholm, Sweden
sUniversity of Eastern Finland, Finland
tSchool of Public Health, Imperial College, London, United Kingdom
uNuclear Medicine Department, University Hospital of Toulouse (CHU-Toulouse), Toulouse, France
vToNIC, Toulouse NeuroImaging Center, Universite de Toulouse, Inserm, UPS, Toulouse, France
wCentre for Clinical Brain Sciences, Department of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom
xNuclear Medicine IRA, Medical Radiation Physics and Nuclear Medicine Imaging, Karolinska University Hospital, Sweden
yAlzheimer Center and Department of Neurology, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands
zExperimental Medicine, Janssen Pharmaceutica NV, Beerse, Belgium
aaInstitute of Neurology, University College London, London, United Kingdom
abPiramal Imaging, Clinical Research and Development, Berlin, Germany
acGerontopole of Toulouse, University Hospital of Toulouse (CHU-Toulouse), Toulouse, France
adUMR INSERM 1027, University of Toulouse III, Toulouse, France
aeDivision of Psychiatry, University College London, London, United Kingdom
afEssex Partnership University NHS Foundation Trust, United Kingdom
agPiramal Imaging, Market Access and HEOR, Berlin, Germany*Corresponding author. Tel.: 141 22 372 58 01; Fax:---.
E-mail address: giovanni.frisoni@unige.ch
https://doi.org/10.1016/j.jalz.2018.09.003
1552-5260/ 2018 Published by Elsevier Inc. on behalf of the Alzheimer’s Association.
FLA 5.5.0 DTD  JALZ2756_proof  16 October 2018  7:20 pm  ce
Q4
Q5






















































































195clinical utility and cost-effectiveness. The Amyloid Imaging to Prevent Alzheimer’s Disease–
Diagnostic and Patient Management Study (AMYPAD-DPMS) is designed to fill this gap.
Methods: AMYPAD-DPMS is a phase 4, multicenter, prospective, randomized controlled study.
Nine hundred patients with subjective cognitive decline plus, mild cognitive impairment, and demen-
tia possibly due to Alzheimer’s disease will be randomized to ARM1, amyloid-PET performed early
in the diagnostic workup; ARM2, amyloid-PET performed after 8 months; and ARM3, amyloid-PET
performed whenever the physician chooses to do so.
Endpoints: The primary endpoint is the difference between ARM1 and ARM2 in the proportion of
patients receiving a very-high-confidence etiologic diagnosis after 3 months. Secondary endpoints
address diagnosis and diagnostic confidence, diagnostic/therapeutic management, health economics
and patient-related outcomes, and methods for image quantitation.
Expected Impacts: AMYPAD-DPMSwill supply physicians and health care payers with real-world
data to plan management decisions.
 2018 Published by Elsevier Inc. on behalf of the Alzheimer’s Association.196














































Amyloid-PET can reliably detect senile plaques made of
amyloid-b [1–3], hallmarks of Alzheimer’s disease (AD),
and fluorinated ligands are approved in several countries
[4–9]. Nevertheless, reimbursement is lagging due to the
lack of definitive evidence supporting its clinical utility
and cost-effectiveness in the diagnostic workup.
An observational study in the USA, the Imaging
Dementia-Evidence for Amyloid Scanning (IDEAS) study
[10], aims to assess the clinical utility of amyloid-PET on
more than 18,000 patients aged 651 years meeting the
appropriate use criteria for amyloid-PET prescription pub-
lished by the Amyloid Imaging Taskforce (AIT) [11,12].
This study is currently assessing the impact of amyloid-
PET on patient management (change of at least one of the
following endpoints: AD drug therapy, other drug therapy,
and counseling about safety and future planning) and on
the use of health care resources (hospital admissions and
emergency room visits) in amyloid-PET-known compared
to matched patients not undergoing amyloid-PET over
12 months. Preliminary results on the first 3979 patients
showed a considerable change in patient management in
68% of mild cognitive impairment (MCI) and in 66% of de-
mentia patients following amyloid-PET [13]. These results
are in good agreement with a recent review on the clinical
utility of amyloid imaging, reporting a change in patient
management in 64% of patients, as well as a change in diag-
nosis in 29%, and in medications in 38% of patients [14].
Amyloid Imaging to Prevent Alzheimer’s Disease (AMY-
PAD) is a collaborative research initiative aimed to improve
diagnosis and management and to accelerate the develop-
ment of disease-modifying treatments through the utilization
of amyloid-PET [15]. This 5-year program is part of the
Innovative Medicines Initiative, a joint undertaking between
the European Commission and the European Federation ofFLA 5.5.0 DTD  JALZ2756_proof Pharmaceutical Industries and Associations. A total of
6000 scans will be performed in thewhole AMYPAD project
split 50:50 between the PET imaging agents [18F]florbetaben
(trade name NeuraCeq, Piramal Imaging) and [18F]fluteme-
tamol (trade name Vizamyl, GE Healthcare). AMYPADwill
have two main clinical studies. In the prognostic and natural
history study (AMYPAD-PNHS), amyloid-PET will be car-
ried out in the context of its sister project EPAD (European
Prevention of Alzheimer’s Dementia) aiming to set up a
cohort of nondemented persons at high risk of AD who
will be enrolled in preventive pharmacologic trials [16].
The second component is the Diagnostic and Patient Man-
agement Study (AMYPAD-DPMS), which aims to investi-
gate the clinical utility of amyloid-PET in a controlled but
realistic clinical setting of patients with subjective cognitive
decline (SCD) plus (SCD1) [17], MCI, and dementia
possibly due to AD. This article aims to describe the ratio-
nale, design, methods, and expected results and impact of
AMYPAD-DPMS.2. Rationale
The clinical-scientific space of AMYPAD-DPMS is that of
the introduction of amyloid-PET in the routine clinical prac-
tice in the diagnostic workup of patients with suspect AD.
Despite overwhelming evidence on the analytical [1–3] and
clinical validity of amyloid-PET [18], evidence on the clinical
utility is still limited (Table S1 in Supplementary Material).
Indeed, most of the studies published so far [19–28] are
only observational and lack proper study designs (e.g.,
parallel control groups) for a systematic and definitive
assessment of the amyloid-PET clinical utility. Moreover,
and most importantly, evidence on real-life effectiveness
and cost-effectiveness in the absence of disease-modifying











Fig. 1. Diagnostic reasoning framework in AMYPAD-DPMS. Abbrevia-
tions: AD, Alzheimer’s disease; AMYPAD-DPMS, Amyloid Imaging to
Prevent Alzheimer’s Disease–Diagnostic and Patient Management Study.






































































































































377strong evidence, but its results are not directly transferable to
the European health care setting, which is quite different from
that of the USA.
As a consequence of the limited available evidence,
payers (e.g., public health care systems or private health
care insurances) are either not reimbursing the amyloid-
PET examination or restricting reimbursement to extremely
narrow indications (e.g., very specific categories of patients)
or at the rate of the much cheaper FDG-PET (covering only
part of the costs, e.g., the PET scan itself, and leaving the re-
maining costs, e.g., the amyloid tracer purchase, to be paid by
the patient) [30]. AMYPAD-DPMS aims to fill this evidence
gap by testing the hypothesis that patients undergoing
amyloid-PET early on in their diagnostic workup receive a
very-high-confidence etiologic diagnosis earlier than pa-
tients undergoing amyloid-PET later or never, and by
providing relevant information about health economics vari-
ables (savings on other diagnostic examinations, unneces-
sary drug treatment, hospitalizations and other medical
consultations, etc.). We also hypothesize that earlier and
more confident diagnosis is followed bymore frequent inclu-
sion in AD clinical trials, earlier and more frequent adoption
of pharmacologic and nonpharmacologic symptomatic treat-
ments, lower use of medical resources, and better patient
quality of life (lower anxiety, better coping). The diagnostic
questions we wish to address are those related to the tradi-
tional differential diagnosis of AD in patients with dementia,
early and differential diagnosis of AD in patients with MCI,
and to themore contentious issue of dementia risk profiling in
SCD. In AMYPAD-DPMS, patients with SCD satisfy the
Subjective Cognitive Decline Initiative (SCD-I) Working
Group criteria for SCD1 (self-reported cognitive complaint,
plus features increasing the likelihood of preclinical AD)
[17]. Patients with SCD1 have a higher rate of conversion
to MCI than patients with SCD not meeting the criteria for
SCD1 (18.9% vs. 5.6% [31]). The study design rests on
some assumptions.
1. Generalizability of results.Although the design of any
clinical trial inevitably diverges from clinical practice,
we assume that the results of a study designed by
leveraging on the typical memory clinic practice
would be applicable to the practices of general mem-
ory clinics.
2. Diagnostic workup. We assume that memory clinics
worldwide share a typical workup featuring the
following components: a first consultation by the med-
ical specialist collecting history, carrying out screening
cognitive tests, neurological physical and psychiatric
assessment, and prescription of complementary exami-
nations; based on information collected during the first
consultation, a syndromic diagnosis (SCD, MCI, de-
mentia) can be made; a structural scan (CT or MRI)
done in virtually 100% of cases and preliminary to
further biomarker assessment; the prescription or
collection of biomarkers (e.g., cerebrospinal fluidFLA 5.5.0 DTD  JALZ2756_proof  16and/or FDG-PET) takes place after the structural scan
in a variable number of cases; the diagnostic workup
strives to achieve an etiologic diagnosis on top of the
syndromic diagnosis; once the specialist is confident
enough, the etiologic diagnosis is communicated to
the patient, and prescription of pharmacologic and non-
pharmacologic treatments takes place at the end of the
diagnostic workup, in general within 3 months and at
the latest within 6 months from the first visit.
3. Diagnostic reasoning framework.We assume that spe-
cialists share the abstract notion of what constitutes a
high/low likelihood that symptoms are due to AD; and
that the higher the likelihood, the higher the confi-
dence in an etiologic diagnosis of AD, the lower the
likelihood, the higher the confidence in an etiologic
diagnosis of non-AD (Fig. 1). We also assume that
confidence in an etiologic diagnosis of AD/non-AD
can be loosely operationalized into a percentage of
confidence; and specialists aim to achieve the highest
possible confidence, ideally 90%.
4. Diagnostic criteria. We Qassume that most memory
clinics refer to the 2011 NIA-AA criteria [32–34] for
the AD diagnosis, either implicitly or explicitly. The
recent revision of the NIA-AA criteria [35], with its
agnostic descriptive approach, will likely change
research and clinical approaches to AD. When this
happens, the AMYPAD-DPMS results may need to
be reinterpreted.
5. Consequences of an etiologic diagnosis.We Qassume that
an accurate etiologic diagnosis can potentially impact
management in patients with dementia (especially
regarding acetylcholinesterase inhibitor, AChEI,October 2018  7:20 pm  ce














































































































487treatment); while there is lesser agreement on the phar-
macologicmanagement of patientswithMCI, a number
of specialists prescribe AChEIs off-label; and an etio-
logic diagnosis is not possible in SCD1; however, in
this population, amyloid-PET could be used for risk
profiling [36]. Moreover, while a positive scan can
confirm a previous AD diagnosis or increase the likeli-
hood of AD, a negative scan excludes AD from the dif-
ferential diagnosis potentially leading to discharge in
patientswith SCD, and toother diagnostic examinations
or a milder prognosis in those with MCI or dementia
[37].
6. Frequency of amyloid pathology. The prevalence of
amyloid pathology increases from age 50 to 90 years
from 12% to 43% in SCD (may be higher in
SCD1), and from 27% to 71% in MCI [38], whereas
decreases from age 50 to 90 years from 93% to 79% in
patients with AD dementia [39].
3. Methods
3.1. Participants
Nine hundred persons 50 to 85 years of age will be
enrolled: 300 SCD1, 300 MCI, and 300 with dementia
where AD is in the differential diagnosis. All consecutive pa-
tients coming to observation to a participating memory
clinic with a request for diagnosis and fulfilling inclusion
and exclusion criteria will be eligible for enrollment. Inclu-
sion and exclusion criteria (Tables 1 and 2) were drafted to
include all patients with cognitive complaints eligible to un-
dergo a diagnostic workup, with the possibility that com-
plaints are due to AD, and where an accurate etiologic
diagnosis may have some impact on patient management
























The 8 EPAD memory clinics will enroll patients to
AMYPAD-DPMS (Fig. 2). We expect each center contrib-
uting 112 participants. We acknowledge that some features
of participating academic memory clinics might limit the
generalizability of the results of the study to the nonaca-
demic memory clinics consulting the large majority of pa-
tients from the general population. Indeed, some academic
memory clinics work solely or mainly as tertiary referral ser-
vices, where the most complex patients are referred from
secondary referral nonacademic services. Moreover, the
greater availability of technology and facilities allows
EPAD memory clinics a much more biomarker-oriented
diagnostic workup not always representative of the workup
of nonacademic clinics. To improve the generalizability of
the results, such academic memory clinics will engage affil-
iated nonacademic clinics for patients’ recruitment and man-
agement.FLA 5.5.0 DTD  JALZ2756_proof 3.3. Study design
AMYPAD-DPMS is a phase 4, multicenter, prospective,
interventional, randomized controlled study. The study
design is tightly linked to clinical procedures. After the first
clinical consultation, where MRI or CT is either already
available or prescribed, study screening takes place with in-
clusion/exclusion criteria check and informed consent
explanation and signature. The baseline visit will take place
within 14 days of screening. Here, patients are stratified into
the three syndromic groups of SCD1, MCI, and dementia
possibly due to AD and randomized soon thereafter into
the three study arms (Fig. 3) using permuted blocks to assure
that each arm is balanced to the syndromic groups such that
each arm will include 100 SCD1, 100MCI, and 100 demen-
tia patients.
 ARM1 patients will undergo amyloid-PET early in the
diagnostic workup (within 4 weeks from baseline), and
the examination results are provided to the managing
physician who will either order additional diagnostic
tests or disclose diagnosis and set up a management
plan.
 ARM2 patients will undergo amyloid-PET late in the
diagnostic workup (8 months after baseline), and the
managing physician can start the diagnostic workup
either ordering other diagnostic tests or disclosing
diagnosis and initiate a management plan according
to usual local practices.
 In ARM3, the managing physician will be free to order
amyloid-PET whenever he/she will feel fit, if at all.
Here, amyloid-PET will be just yet another diagnostic
examination available to the managing physician in
addition to the usual armamentarium.
At the end of month 3 from baseline, the steps of the clin-
ical workup carried out so far will be recorded into the study
eCRF (electronic case report form), including syndromic
and etiologic diagnoses, diagnostic confidence, likelihood
that the symptoms are due to AD, and management plan
all made by the managing physicians. At this point in
time, the managing physician will have 3 more months to
complete the diagnostic workup, disclose diagnosis, and
set up a management plan (but we have considered the pos-
sibility that this may exceptionally not be the case). At the
end of months 6 and 13 from baseline, the steps of the clin-
ical workup will again be recorded into the study eCRF,
together with health economics and patient-centered out-
comes (Table 3). ARM1 patients will be invited to a second
amyloid-PET scan that will take place 18 months after the
first one and will contribute to the exploratory outcome of
disease modeling central to the AMYPAD-PNHS study.
Although the meaning of ARM1 and ARM2 is relatively
straightforward, ARM3 deserves specific discussion. A sur-
vey in 37 academic memory clinics of the European Alz-
heimer’s Disease Consortium (EADC) found that 60% of
dementia specialists feel very or extremely comfortable to16 October 2018  7:20 pm  ce
Table 1
Major inclusion and exclusion criteria
Inclusion criteria: To be enrolled in the study, patients must meet all the following criteria.
 The patient can be of any sex, gender, race, or ethnicity.
 The patient must have a complaint (reported by the patient or by a caregiver) of cognitive problems that are considered by the managing physician to be
possibly due to AD.
B The patient must be entering a diagnostic assessment for the cognitive complaint.
B The managing physician must feel that knowledge of the patient’s brain amyloid status may increase diagnostic confidence and alter diagnosis and
management.
B In some centers, the patient may receive diagnostic workup before being screened for this study. These patients can be enrolled in the study; however, if
they are assigned to the early amyloid-PETarm, the results of that workup must not be made available to the managing physician before the managing
physician reviews the results of the amyloid-PET scan.
 The patient must satisfy the diagnostic criteria for one of the following (see Table 3): SCD-Plus, MCI, and dementia where AD is in the differential
diagnosis.
 The patient has undergone a dementia blood workup or will have one before amyloid-PET.
 The patient has an MRI and/or CT scan (not older than 12 months) or will undergo one before amyloid-PET.
 The patient can complete all clinical visits according to the protocol.
 The patient can tolerate a 20-minute amyloid-PET scan.
 The patient (or a legal representative) provides informed consent for study participation and data source verification. In case the patient is randomized to
the early amyloid-PET arm, a new informed consent should be signed before the second imaging session.
 If the patient has dementia, a study partner is available for the duration of the protocol.
 The patient wants to know the amyloid-PET result.
Exclusion criteria: Patients must be excluded from participating in this study if they meet any of the following criteria.
 The patient has another confirmed condition that can fully account for the cognitive impairment (neuroinflammatory, neuroinfective, or neurodegenerative
disease; multiple sclerosis; genetic disorders; HIV; brain injuries; neurosurgery after-effects; major depressive episode; schizoaffective disorder;
delusional disorder; delirium).
 The patient comes to observation for reasons other than diagnosis (disability assessment for social aids, cognitive assessment for driving license, etc.).
 The patient had a previous amyloid-b imaging scan and/or has had other AD biomarker workup (fluorodeoxyglucose [FDG]-PET and/or cerebrospinal
fluid analysis) before screening. In some centers, the patient may receive a diagnostic workup before screening. These patients can be enrolled if the
investigator is blind to the results until after randomization or (for patients in the early amyloid-PETarm) until after reviewing the results of amyloid-PET
imaging.
 The patient has a life-threatening unstable medical disease or psychiatric condition that could lead to difficulty in complying with the protocol.
 The patient is currently receiving an investigational pharmaceutical product or has participated in a clinical trial with an investigational pharmaceutical
product within 30 days before screening and/or was administered a radiopharmaceutical within 10 radioactive half-lives before study drug administration
in this study.
 The patient is a woman who is pregnant, planning to become pregnant, or lactating.
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; SCD, subjective cognitive decline.


























































































































633deliver a diagnosis of prodromal AD (or MCI due to AD) on
the basis of standard assessment and amyloid-PET alone,
while this proportion increases to 75% if also medial tempo-
ral atrophy on MRI or cortical hypometabolism on FDG-
PET is present [42]. However, data are not available on the
use of amyloid-PET in realistic settings with no budgetary
or reimbursement constraints. ARM3 will allow the explora-
tion of spontaneous and unrestricted ordering of amyloid-
PET as well as to assess the dynamic change that might
come with increasing familiarity with the examination












The primary endpoint is to test the hypothesis that the
proportion of patients for whom the managing physician
reaches an etiologic diagnosis with very high confidence
(90%) at 3 months after baseline is higher for patients
who underwent amyloid-PET imaging shortly after base-
line (ARM1) than for patients who have not yet under-
gone amyloid-PET imaging (ARM2). DiagnosticFLA 5.5.0 DTD  JALZ2756_proof confidence will be rated by the managing physician using
a visual analogue scale ranging from 0% to 100%. A
diagnostic confidence of 90% is operationalized as an in-
termediate level between that of the pathological diag-
nostic gold standard (100%) and the nonbiomarker-
assisted NINCDS-ADRDA probable AD diagnosis
(80%). The primary endpoint does not directly encompass
patient’s quality of life or health-related outcomes. We as-
sume that physician’s high diagnostic confidence based on
valid biomarkers is a proxy of accurate diagnosis, and that
this, in turn, is associated with better quality of life and
health-related outcomes. Although often undemonstrated,
similar assumptions are frequent in diagnostic studies,
due to the exceedingly complex and expensive implemen-
tation of clinical utility trials. Secondary and exploratory
endpoints are listed in Table 3.3.5. Amyloid-PET result disclosure to patients with SCD1
The disclosure of amyloid-PET results to patients with
MCI and dementia will follow the disclosure protocols in16 October 2018  7:20 pm  ce
Table 2
Inclusion and exclusion criteria specific to SCD1, MCI, and dementia where AD is in the differential diagnosis
SCD1 (modified from SCD-I Working Group criteria [17])
Inclusion criteria for SCD1
 Age between 60 and 85 years.
 The patient has perceived a decline in memory over time.
 The onset of the SCD is within the previous 5 years and the duration is .6 months.
 The Mini–Mental State Examination score is 27 to 30 out of 30 (MMSE score  27 is the optimal cutoff in terms of accuracy in detecting cognitive
dysfunction; sensitivity: 0.89; specificity: 0.91; overall classification rate: 90% [40]).
 The clinical examination and neuropsychological assessment exclude MCI.
 Cognitive decline has been confirmed by an informant.
 The patient (or caregiver) has expressed concerns (worries) about the cognitive symptoms.
 Consultation has been actively requested by the patient or an informant.
Exclusion criteria for SCD1
 Current or past psychiatric disorders according to ICD 10 (including major depression, anxiety disorder, substance-related disorders, schizophrenia,
bipolar disorder, adult ADHD, posttraumatic stress disorder). However, a depressive episode, an anxiety disorder, or a substance-related disorder that
occurred .5 years earlier and in no temporal association with the onset of SCD is not a criterion for exclusion.
 Current or past history of a neurologic disease with known potential impact on cognition.
 MRI lesions that would not be consistent with a diagnosis of AD.
 Current use of medicationwith known effect on cognition, including sedatives and drugs with anticholinergic effect, if the clinician believes that the use of
those drugs is the cause of cognitive impairment.
MCI (NIA-AA [33])
Inclusion criteria for MCI
 Age between 50 and 85 years.
 Concern regarding a change in cognition, as expressed by the patient, a proxy, or a physician.
 Impairment in one or more cognitive domains, as defined by neuropsychological test scores 1.5 SD below the age- and education-specific mean.
 Preservation of independence in functional abilities.
 No dementia.
Exclusion criteria for MCI
 Same as those of Table 1.
Dementia where AD is in the differential diagnosis (NIA-AA [34])
Inclusion criteria for probable AD dementia
 Age between 50 and 85 years.
 Insidious onset.
 Clear-cut history of worsening of cognition by report or observation.
 The initial and most prominent cognitive deficits are evident on history and examination.
 Presentation can be amnestic or nonamnestic (language, visuospatial, executive function, etc).
 The diagnosis of probable AD dementia should not apply when there is evidence of substantial concomitant cerebrovascular disease, dementia with Lewy
bodies, behavioral variant of frontotemporal dementia, semantic variant primary progressive aphasia or nonfluent/agrammatic variant primary progressive
aphasia, evidence for another concurrent, active neurological disease, or non-neurological medical comorbidity, or use of medication that could have a
substantial effect on cognition.
Inclusion criteria for possible AD dementia
 Age between 50 and 85 years.
 Atypical course (either a sudden onset of cognitive impairment or insufficient historical details or objective cognitive documentation of progressive
decline).
Exclusion criteria for probable and possible AD dementia
 Same as those of Table 1 Q10.
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; SCD, subjective cognitive decline.
NOTE.We applied different entry ages for SCD1, andMCI and dementia patients. As to SCD1, the entry agewas set at 60 years, consistently with the SCD-I
Working Group criteria for SCD1, to limit the prevalence of psychiatric cases (SCD at younger ages is enriched with persons with psychiatric conditions,
whereas at older ages is enriched with neurodegenerative conditions) [17]. As to MCI and dementia, the entry age was set at 50 years to assess the clinical utility
of amyloid-PET also in early-onset patients with objective cognitive impairment (and thus probable underlying neurodegenerative conditions).






































































































































779place in the participating memory clinics. Importantly, the
specialists’ perception of the utility of amyloid-PET is
remarkably homogenous across the memory clinics of the
EADC, of which the AMYPAD-DPMS participating clinics
are part [42]. Much more uncertain is the disclosure of
amyloid-PET results to patients with SCD1. Indeed, the
role of amyloid in the pathophysiological cascade ultimately
leading to dementia is still unclear: prevalence of amyloid
pathology in cognitively unimpaired people varies fromFLA 5.5.0 DTD  JALZ2756_proof 10% (50 years) to 44% (90 years) [38], and many will die
without overt symptoms of AD. The recent NIA-AA criteria
labels cognitively unimpaired persons with isolated
amyloidosis as “Alzheimer’s pathologic change” [35], a
somewhat intermediate stance. Whatever the pathophysi-
ology and lexicon, brain amyloidosis is undeniably a power-
ful risk factor for adverse cognitive outcomes.
The AMYPAD-DPMS consortium acknowledges that the










Fig. 2. Participating memory clinics.





































































































































912patients with SCD1 are far from clear and are subject to
several personal, clinical, social, and cultural modulating
factors. According to the inclusion criteria, only patients
whowant to know their amyloid-PET result will be enrolled.
We assume that this criterion allows to generalize our results
to the clinical practice of memory clinics, where patients
proactively seek medical help. Indeed, although there may
be exceptions, we assume that these patients expect to un-
dergo medical examinations and wish to know their results.
The consortium agreed that in patients with SCD1, although
formulating an etiological diagnosis is not appropriate in the
routine clinical practice, the managing physicians will be
asked to express their opinion on SCD being due to AD;
amyloid-PET can be used for risk profiling; the disclosure
of the result of amyloid-PET should be in terms of increased
or decreased risk of AD dementia; disclosure is recommen-
ded and should follow guidelines adapted from those used in
the A4 trial [43] (Tables S2 and S3 in Supplementary
Material). Recent evidence suggests that the disclosure of
the amyloid status in cognitively unimpaired patients is asso-
ciated with a low risk of psychological harm [44], and that
the prognostic uncertainty of amyloid-PET is correctly un-
derstood by two-thirds of patients [45]. The information
delivered by the managing physician to each SCD1 partic-
ipant will be recorded, based on the items listed in our guide-
lines. In exceptional cases, it is possible not to disclose (e.g.,
a patient changes her/his mind during the study, or the man-FLA 5.5.0 DTD  JALZ2756_proof aging physician does not consider it appropriate anymore).
These cases will be documented and justified but will not
be removed from the study (consistently with the
intention-to-treat approach: we include in our analyses every
subject randomized according to randomized treatment
assignment). Assuming that the physicians’ beliefs on the
pathophysiological role of amyloid in neurodegenerative
diseases [46] can affect the disclosure of amyloid-
associated risk, the managing physicians’ beliefs will be re-
corded as well by asking them to fill in a questionnaire.3.6. Statistics
For each of the three syndromic groups, the difference be-
tween ARM1 and ARM2 in the proportion of patients with a
diagnostic confidence 90% at 3 months will be evaluated
with a c2 test with overall significance level of 5%. A Bon-
ferroni correction will be applied to the stratum-specific
evaluation to control for family-wise type I error rate at
5%. The statistical evaluation will achieve a power of 80%
when the assumed difference is 25% and not more than
10% of the patients withdraw before the endpoint is reached.
Heterogeneity with respect to the estimated difference be-
tween arms will be examined with Breslow-Day test of ho-
mogeneity. If heterogeneity is significant, it will be











Fig. 3. Design. Abbreviations: AMYPAD-DPMS, Amyloid Imaging to Prevent Alzheimer’s Disease–Diagnostic and Patient Management Study; CSF, cere-
brospinal fluid; Dx, diagnosis; T, time point; V, visit; eCRF, electronic case report form; QoL, quality of life; SCD1, subjective cognitive decline plus. We
acknowledge that in some participating clinics, an extensive biomarker workup (e.g., CSF) is done on the first visit, before the patient can be screened for
AMYPAD-DPMS. We stipulate that these patients can be enrolled in the study, but, if assigned to ARM1, the results of that workup will not be made available
to the managing physician before they will be informed of the amyloid-PET result.

























































































































1034The secondary diagnosis and diagnostic confidence out-
comes are time-to-event measures, and differences between
arms will be tested with the log-rank test. Dropout is ac-
counted for by censoring at the time of the last study visit.
Differences between arms in the diagnostic/therapeutic
management, health economics, and patient-centered out-
comes will be evaluated with a c2 test, t-test, or Mann-
Whitney test whichever is appropriate. Longitudinal trends
of the diagnostic/therapeutic management, health eco-
nomics, and patient-centered outcomes will be studied by
mixed effects analyses that allow for patient-specific and
center-specific effects and that can be applied to interval,
dichotomous, and count data. Point estimates will be pre-
sented together with 95% Wald confidence intervals. Bon-
ferroni corrections for multiple testing will be applied













10474. Expected results and impact
The major impact of AMYPAD-DPMS will consist in
providing empirical evidence on the effect of amyloid-
PET on diagnostic thinking, management outcomes, pa-
tient outcomes, and use of health care resources. The ev-
idence will be used by physicians for more informed
management decisions and by health care payers for de-
cisions about reimbursement of amyloid-PET. This will
be a unique contribution in that the only other largeFLA 5.5.0 DTD  JALZ2756_proof study on this topic, IDEAS in the USA, differs under
several key aspects. IDEAS is a naturalistic study where
18,448 Medicare patients satisfying the AIT appropriate
use criteria [11,12] recruited from specialty practices
undergo amyloid-PET. Outcomes are change in a man-
agement composite endpoint and reduction in hospitaliza-
tion and emergency department visits. Controls are
selected based on “propensity matching” of patients
with similar sociodemographic and clinical features who
did not undergo amyloid-PET.
The randomized and controlled design of AMYPAD-
DPMS will provide stronger evidence on the difference
of primary and secondary outcomes between patients un-
dergoing early or late amyloid-PET. AMYPAD-DPMS
will not limit amyloid-PET to patients considered appro-
priate by the AIT. Indeed, preliminary evidence indicates
an impact of amyloid-PET on change of diagnosis and
management also in AIT-inappropriate patients [47]. The
inclusion of patients with SCD1, clearly an AIT-
inappropriate group, will allow to investigate the use and
interpretation of amyloid-PET in these patients increas-
ingly requiring medical opinion in memory clinics and of
increasing interest for intervention trials, who will pose a
major challenge for the near future. Indeed, patients with
SCD have different needs than those with cognitive/func-
tional impairment, and recent efforts are moving toward
the creation of the so-called “brain health clinics/services”
[48], clinical facilities with specific aims and missions16 October 2018  7:20 pm  ce
Table 3
Secondary [A] and exploratory [B] endpoints
[A] Secondary endpoints
Diagnosis and diagnostic confidence
To assess the impact of amyloid-PET imaging on other diagnosis-related metrics:
 Time to communicate to the patient an etiologic diagnosis with very high confidence (90%);
 Changes in the managing physician’s etiologic diagnosis over time;
 Changes in the managing physician’s diagnostic confidence over time;
 The managing physician’s estimate of the likelihood that the patient’s symptoms are due to AD; and
 How the placement of amyloid-PET imaging in the clinical workup, when the managing physician is given free choice, changes over time.
Diagnostic/therapeutic management
To assess the impact of amyloid-PET imaging on patient management, including
 The number of patients randomized to disease-modifying drug or any other AD clinical trial at 6 months from baseline;
 Change or early adoption of programs and/or pharmacologic treatments aimed to delay the onset or progression of cognitive impairment; and
 Use of medical resources (including but not limited to diagnostic procedures, tests, programs, visits, and hospitalizations).
Health economics and patient-centered outcomes
To assess the impact of amyloid-PET imaging on
 Patient-related outcomes (cognition, anxiety, depression, coping skills, and quality of life);
 Cost of diagnostic workup to the etiologic diagnosis with very high confidence (90%); and
 The number of patients who are discharged from the memory center and the reason for discharge.
Methods for image quantitation
 To test the hypothesis that amyloid load is stable over 18 months.
 To develop standardized methods of image quantitation across the PET tracers (e.g., using the Centiloid scale [41]) to allow pooled analysis of [18F]
florbetaben and [18F]flutemetamol scans across the AMYPAD program.
[B] Exploratory endpoints
 Impact of amyloid-PET according to different cognitive profiles (amnesic vs. nonamnesic).
 Impact of disclosing the amyloid status to patients with SCD1 on quality of life and patient-centered outcomes over time.
 Assessment of the utility of amyloid-PET staging and modeling approaches across diagnostic groups.
 Collection of evidence on the clinical utility of amyloid-PET over other biomarkers to contribute to outline a cost-effective diagnostic algorithm (for
instance, a subsample of patients will undergo amyloid-PET before CSF if the latter is prescribed (ARM1), whereas others will undergo amyloid-PET
after CSF if the latter is prescribed (ARM2). Therefore, we will be able to compare the relative incremental value of amyloid-PETover CSF markers and
vice versa, and to assess whether and how the inclusion of CSF in the diagnostic workup affects the frequency of the subsequent prescription of amyloid-
PET in ARM3).
 Assessment of whether and how the clinical utility and cost-effectiveness of amyloid-PET differ between academic and non-academic memory clinics by
a posteriori stratified analyses (we can expect some differences among different centers in the use and interpretation of the amyloid-PET result depending
on their level of experience).
Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; SCD, subjective cognitive decline.
The likelihood of AD (0–100%) corresponds to the physician’s judgment that the patient’s cognitive impairment (or concern, in SCD1) is due to AD. The
treatment plan may include cognition-specific medications (AChEIs and/or memantine) and noncognition-specific medications (e.g., anxiolytics, hypnotics,
antidepressants, antipsychotics, and anticonvulsants).
See e3.4 in Supplementary Material for further information about the tools used to assess “use of medical resources” and “patient-related outcomes.”






































































































































1181dealing with healthy people and SCD. Data collected
within AMYPAD-DPMS will provide unique evidence
that brain health clinics/services will use to implement
risk assessment and communication protocols. Finally,
the design of ARM3 will allow to investigate the dynamics
over time of specialists’ diagnostic thinking when amyloid-
PET is made available with no restriction. This will provide
key information on the placement of a PET scan in the
diagnostic algorithm, a key topic of interest to the Euro-
pean Medicines Agency and health technology assessment
bodies.
One limitation of this study is that only some European
countries are involved, and these differ for health systems,
policies, and laws. These aspects may impact on some of
our secondary endpoints (diagnostic/therapeutic manage-
ment, and health economics and patient-centered outcomes)
and prevent us from generalizing our results to all Europe.FLA 5.5.0 DTD  JALZ2756_proof However, such differences will not impact on the primary
endpoint (diagnostic confidence).
To conclude, in the validation process of diagnostic bio-
markers, the impact of their use on patient’s health outcomes
and quality of life and cost-effectiveness outcomes is para-
mount to payers [49]. The focus of AMYPAD-DPMS on
such outcomes will allow to collect structured and reliable
information that will critically contribute to payers’ reim-
bursement decisions.Acknowledgments
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1. Systematic review: Evidence on the amyloid-PET
clinical utility is still limited: most of the studies
published so far are only observational and lack
proper study designs for a systematic and definitive
assessment. Moreover, and most importantly, evi-
dence on real-life effectiveness and cost-
effectiveness in the absence of disease-modifying
therapies is lacking. The Amyloid Imaging to Pre-
vent Alzheimer’s Disease–Diagnostic and Patient
Management Study (AMYPAD-DPMS) is designed
to fill this gap.
2. Interpretation: AMYPAD-DPMS will provide
empirical evidence on the effect of amyloid-PET on
diagnostic thinking, management outcomes, patient
outcomes, and use of health care resources. More-
over, the randomized and controlled design of
AMYPAD-DPMS will provide strong evidence on
the difference of the outcomes between patients un-
dergoing early and late amyloid-PET.
3. Future directions: AMYPAD-DPMS will allow to
collect structured and reliable information that will
be used by physicians for more informed manage-
ment decision and will critically contribute to payers’
amyloid-PET reimbursement decisions.References Q
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